The present study deals with the development and evaluation of controlled porosity osmotic pump (CPOP) tablets of ZidovudineLamivudine. Wet granulation method was used for the development of core tablets. Core tablets were incorporated with HPMCE5 LV polymer, different concentrations of fructose as osmogen and additives. The CPOP tablets were coated with cellulose acetate as a wall forming material, polyethylene glycol as flux regulating agent, and sorbitol acts as pore forming material in SPM. The formulated tablets were evaluated for FTIR, DSC, pre-compression parameters, post compression parameters, in vitro drug release study and scanning electron microscopy study. The optimized formulation had no significant effect on the p H and agitation intensity, but depends on the osmotic pressure of dissolution media indicated that mechanism of drug release. SEM images revealed that no pores were found before dissolution and after dissolution had shown the porous nature of the membrane. Short term stability study at 40±2ºC /75±5% RH for the months on the CF4 formulation indicated that there was no significant change weight variation, % friability, drug content and in vitro drug release.
INRODUCTION
Controlled release dosage forms is the part of modified drug release dosage form which covers a wide range of prolonged 1 action which provide continuous release of their active ingredients at predetermined rate and predetermined time. Out of various controlled drug delivery systems osmotic controlled drug delivery system (OCDDS) utilizes principle of osmotic pressure 2 to control the delivery of active ingredients. The drug released from OCDDS is independent of p H , hydrodynamic condition of the body and agitation intensity.
The present study is to develop controlled porosity osmotic pump tablets. CPOP tablets were developed where the delivery orifices were formed by the incorporation of a leachable component 3 in SPM. The core is coated with cellulose acetate containing in situ micro pore former sorbitol. Once CPOP tablets come in contact with the aqueous environment of biological system the water soluble component dissolves and an osmotic pumping system is created in the core. Hence water diffuses into the core though the micro porous 4 membrane setting up an osmotic gradient and thereby controlling the release of drug.
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Globally AIDS is considered a dangerous disease which is caused by infection with human immune deficiency virus. The final stage of AIDS where the CD4+ count declines to 200cells/µL. Out of various treatments now antiretroviral 5 therapies plays a vital role for controlling the progression of AIDS. Combination therapy is used to be the advanced care of HIV infected patients. The current formulation containing 300 mg Zidovudine and 150 mg of Lamivudine has been formulated as an oral therapy (tablet) for the treatment of HIV-1 infection in adults. The development of this fixed dose combination 6 aims to reduce the number of daily tablets, enhance the compliance therapy and thereby minimizing the risk of emergence of resistance.
MATERIALS AND METHODS

Materials
Zidovudine and Lamivudine were obtained from Hetero Drugs Pvt. Ltd. India. Fructose and mannitol were purchased from Qualigens Fine Chemicals, India. Cellulose acetate (CA) was obtained from Eastman Chemical Inc, Kingsport, TN. Sorbitol, HPMC E5 LV, magnesium stearate, talc and polyethylene glycol (PEG) 400, 600, 4000, 6000 were purchased from S.D. Fine Chemicals Ltd, Mumbai, India. Microcrystaline cellulose (MCC) and starch are purchased from Signet Pharma, Mumbai, India. All other solvents and reagents used were of analytical grade.
Compatibility studies Fourier Transform Infrared Spectroscopy (FTIR)
In this method individual samples as well as the mixture 7 of drug and excipients were ground mixed thoroughly with potassium bromide (1:100) for 3-5 minutes in a mortar and compressed into disc by applying pressure of 10 kg/cm to form a transparent pellet in hydraulic press. The pellet was kept in the sample holder and scanned from 4000 to 400 cm -1 in FTIR spectrophotometer (Bruker, Germany).
Differential Scanning Calorimetry (DSC)
Physical mixtures of drug and individual excipients in the ratio of 1:1 were taken and examined in DSC (Shimadzu DSC-50, Japan).Individual samples as well as physical mixture of drug and excipients 8 were weighed to about 5mg in DSC pan. The sample pan was crimped for effective heat conduction and scanned in the temperature range of 50-300 0 C. Heating rate of 20 0 C min -1 was used and the thermogram obtained was reviewed for evidence of any interactions.
Methods
Preparation of CPOP tablets
Wet granulation technique was used to develop CPOP core tablets. Accurately weighed quantities of ingredients mentioned in Table 1 
Evaluation of granules
The prepared granules were evaluated for pre compression parameters such as angle of repose, bulk density, tapped density and compressibility index (Carr's index). Fixed funnel method was used to determine angle of repose. The bulk density and tapped density were determined by bulk density apparatus (Sisco, India).
The Carr's index can be calculated by the following formula.
%Carr's index 100 (1) Where e t is the tapped density of granules and e b is bulk density of granules.
Hausner's ratio can be calculated by the taking the ratio of tapped density to the ratio of bulk density 9 .
Evaluation of tablets 10
Thickness
The thickness of individual tablets is measured by using vernier caliper (Absolute digimatic, Mitutoyo Corp. Japan).The limit of the thickness deviation of each tablet is 5%.
Measurement of coat thickness
Film was isolated from the tablets after 18hs of dissolution and dried at 40 0 C for 1h.Thickness was measured by using electronic digital calipers (Absolute digimatic, Mitutoyo Corp. Japan)
Hardness
The hardness of tablets can be determined by using Monsanto hardness tester (Sisco, India).
Friability test
Friability test of tablets was performed in a Roche friabilator (SISCO, India).Twenty tablets of known weight (W 1 ) were de-dusted in plastic chamber of friabilator for a fixed time of 25 rpm for 4 minutes and weighed again of weight (W 2 ).The percentage of friability was calculated using the following equation.
%Friability= (2)
Where, W 1 and W 2 are the weight of the tablets before and after the test respectively.
Weight variation test
The weight variation test is performed by weighing 20 tablets individually calculating the average weight and comparing the individual tablet weights to the average.
The percentage weight deviation was calculated and then compared with USP specifications.
Uniformity of drug content test
Powder is made after triturating 10 CPOP tablets from each batch with mortar and pestle. The powder weight equivalent to one tablet was dissolved in a 100ml volumetric flask filled with 0.1N HCl using magnetic stirrer for 24 h. Solution was filtered though Whatman filter paper No.1 diluted suitably and analyzed spectro photometrically
Diameter of tablet
The diameter of individual tablets is measured by using vernier caliper (Absolute digimatic, Mitutoyo Corp. Japan).
In vitro dissolution studies
The in vitro dissolution 11 studies were carried out using USP apparatus type II (Lab India 8000) at 75 rpm. For the first 2 h the dissolution medium was 0.1N HCl (pH 1.2) and phosphate buffer pH 6.8 from 3-8 h (900 ml), maintained at 37±0.5 0 C. At each time point 5 ml of sample was withdrawn and it was replaced with 5 ml of fresh medium. The drug release at different time interval was measured by UV-visible spectrophotometer (UV-1800, Shimadzu, Japan).
In vitro drug release kinetic studies 12, 13 In order to investigate the mode of release from tablets, the release data of formulation was analyzed zero order kinetics, first order kinetics, Higuchi model and Korsmeyer-Peppas and Hixson-Crowell equations.
Effect of osmogen concentration
Keeping all the parameters for tablet constant different osmogen 14 concentrations were used to prepare tablets. The drug release was compared with the different osmogen concentration of formulated batches by using USP-II dissolution apparatus.
Effect of pore former concentration
SPM for various batches were prepared by taking different concentrations of pore former 15 . The effect of pore former on in vitro release profile is compared as well as number of formation of micropores were observed.
Effect of membrane thickness
Tablets with varying coating thicknesses were developed to demonstrate the effect of coating thickness on drug release. The drug release rate was measured using 0.1N HCl and phosphate buffer pH6.8 as a dissolution medium.
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Effect of flux regulating agents
To assess the effect of flux regulating agents on drug release, formulations were developed with different flux regulating agents keeping all other parameters of tablet constant. The drug release was compared with the different flux regulating agents of formulated batches by using USP-II dissolution apparatus.
Effect of osmotic pressure
The effect of osmotic pressure 16 
Effect of pH
The effect of pH 17 for developed formulations were observed by performing the release studies of optimized formulation in different media 0.1 N HCl (pH 1.2), phosphate buffer pH 6.8 and phosphate buffer in pH 7.4 USP type II dissolution apparatus at 75 rpm. The temperature was maintained at 37±0.5°C. The release was studied at predetermined time intervals.
Effect of agitation intensity
The effect of agitation 18 intensity were observed by performing the release studies of optimized formulation in USP Type II (Paddle) dissolution apparatus containing 0.1NHCl for first 2 h and phosphate buffer pH 6.8 for remaining hours at different rotational speeds of 50,100 and 150 rpm with maintaining temperature at 37±0.5°C.The samples were withdrawn at predetermined intervals and analyzed by UV spectrophotometer.
Scanning Electron Microscopy (SEM)
Coating membranes of formulation were collected before and after complete dissolution of core contents and examined for their porous morphology 19 as well as mechanism of drug release by scanning electron microscope (Leica, Bensheim, Switzerland). Scans were taken at an excitation voltage in SEM fitted with ion sputtering device.
Accelerated stability studies
The packed tablets in air tight container were placed in stability chambers (Thermo lab Scientific equipment Pvt. Ltd., Mumbai, India) maintained at 40±2 0 C/75±5% RH conditions for accelerated testing) for 3 months 20 . Tablets were periodically removed and evaluated for physical characteristics, drug content, in-vitro drug release etc..
RESULTS ANS DISCUSSION FTIR studies:
FTIR spectra (Figure 1) 
Pre compression parameters:
All the compressible excipients for various batches were evaluated for angle of repose, bulk density, tapped density, Carr's index and Hausner's ratio. All the values were within acceptable limits. It is given in Table 3 .
Post compression parameters
Tablets were evaluated for different post compression parameters such as thickness, coat thickness, hardness, %friability, drug content and diameter. All evaluated values were in acceptable limits. It is mentioned in Table  4 . All values are expressed as mean S.D, a n = 3 
Kinetic model
From the kinetic it is observed that all the formulations follow non-Fickian transport mechanism for Zidovudine as the n value is showing more than 0.45 in all formulations. It is shown in table 5.Similarly for Lamivudine the kinetic study was observed showing CF1 non-Fickian transport mechanism and CF2, CF3 and CF4 follow Fickian diffusion mechanism for Lamivudine. It is shown in table 6. 
Effect of osmogen concentration
The concentrations of fructose varied 30, 60, 90, and 120 mg/tab in CF1, CF2, CF3, and CF4 respectively. The cumulative drug release was in order CF4 CF3 CF2 CF1 for both Zidovudine and Lamivudine respectively. It was observed that osmogent enhances the drug release of drug and thus had a direct effect on drug release. The drug release profile was shown in figure 7 for Zidovudine and figure 8 for Lamivudine.
Effect of pore former concentration
Batches CF1 to CF4 the coating composition of pore forming agent of sorbitol were 0%, 10%, 20% ,and 30% w/w of CA of sorbitol respectively. The cumulative drug release was in order CF4 CF3 CF2 CF1 for both zidovudine and lamivudine respectively. It confirms that as the level of pore former increases the membrane becomes more porous after coming contact with aqueous environment resulting in faster drug release. The drug release profile was shown in figure 7 for Zidovudine and figure 8 for Lamivudine.
Effect of membrane thickness
Release profiles of CPOP tablets from various batches varying the coating thickness were evaluated. The order of coating thickness for CF1 to CF4 is CF1 CF2 CF3 CF4. It was clearly evident that drug release was inversely proportional to coating thickness of the semi permeable membrane. The drug release profile was shown in figure 7 for Zidovudine and figure  8 for Lamivudine.
Effect of flux regulating agents
The concentrations of flux regulating agents (PEG400, PEG600, PEG4000, and PEG6000) were 33.3% w/w of CA in coating solution in CF1, CF2, CF3, and CF4 respectively. The cumulative drug release was in order CF4 CF3 CF2 CF1 for both zidovudine and lamivudine respectively. It is observed that type of flux regulating agents have pronounced effect on drug release. Hence the type of flux regulating agents on drug release is written as PEG6000 PEG4000 PEG600 PEG400. The drug release profile was shown in figure 7 for Zidovudine and figure 8 for Lamivudine.
Effect of osmotic pressure on optimized formulation
The results of release studies of optimized formulation in media of different osmotic pressure indicated that the drug release is highly dependent on the osmotic pressure of the release media. The release was inversely related to the osmotic pressure of release media. This finding confirms that the mechanism of drug release is by osmotic pressure. The drug release of Zidovudine for CF4 was found to be 90.32 1.71% for 30 atm, 86.78 1.72% for 60 atm and 82.43 1.74% for 90 atm respectively. It is shown in figure 9 .Similarly the drug release of Lamivudine for CF4 was found to be 93.47 1.74% for 30 atm, 89.16 1.74% for 60 atm and 84.28 1.70% for 90 atm respectively. It is shown in figure 10 .
Effect of pH
The optimized formulation CF4 was subjected to in vitro drug release studies of Zidovudine and Lamivudine differently in buffers with different pH like pH 1.2, pH 6.8 and pH 7.4. It is observed that there is no significant difference in the release profile for Lamivudine and Zidovudine from combination, demonstrating that the developed formulation shows pH independent release.
Effect of agitation intensity
The optimized formulation of CF4 batch was carried out in USP dissolution apparatus type-II at varying rotational speed (50,100 and 150rpm) for Zidovudine and Lamivudine from combination. It shows that the release of both the drugs from CPOP is independent of agitation intensity. 
Scanning Electron Microscopy (SEM)
The coating membrane of the osmotic delivery system before and after dissolution was examined with the help of SEM. Before dissolution (Figure11a) no pores were found in the coating membrane. But after dissolution (Figure11b) comparatively more numbers of pores were found in the membrane might be due to leaching or removal of entrapped drug from the formulation. The porosity nature of the membrane was due to the presence of pore forming agent sorbitol in the formulation. 
Stability studies
From short term stability studies of optimized formulation CF4, it was confirmed that there was no significance changes in physical appearance and drug content. It is shown in table 7. 
